<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03792750</url>
  </required_header>
  <id_info>
    <org_study_id>CA017-076</org_study_id>
    <nct_id>NCT03792750</nct_id>
  </id_info>
  <brief_title>A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors</brief_title>
  <official_title>A Phase 1/2 Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine safety and effectiveness of experimental medication
      BMS-986205 in combination with Nivolumab in patients with cancers that are advanced or have
      spread.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 28, 2018</start_date>
  <completion_date type="Anticipated">June 28, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 28, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events (AE)</measure>
    <time_frame>Approximately 65 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Serious Adverse Events (SAE)</measure>
    <time_frame>Approximately 65 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of AEs leading to discontinuation</measure>
    <time_frame>Approximately 50 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of death</measure>
    <time_frame>Approximately 65 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Laboratory abnormalities</measure>
    <time_frame>Approximately 65 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed serum concentration (Cmax)</measure>
    <time_frame>Approximately 65 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the serum concentration-time curve in 1 dosing interval [AUC(TAU)]</measure>
    <time_frame>Approximately 65 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent total body clearance (CLT/F)</measure>
    <time_frame>Approximately 65 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent volume of distribution at steady-state (Vss/F)</measure>
    <time_frame>Approximately 65 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Accumulation index, calculated based on ratio of AUC(TAU) and Cmax at steady state to after the first dose (AI)</measure>
    <time_frame>Approximately 65 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of maximum observed serum concentration (Tmax)</measure>
    <time_frame>Approximately 65 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Trough observed serum concentration at the end of the dosing interval (Ctrough)</measure>
    <time_frame>Approximately 65 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>10.Percent urinary recovery over 24 hours corrected for molecular weight (%UR)</measure>
    <time_frame>Approximately 65 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-drug antibody (ADA) to Nivolumab</measure>
    <time_frame>Approximately 65 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kynurenine serum levels</measure>
    <time_frame>Approximately 50 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tryptophan serum levels</measure>
    <time_frame>Approximately 50 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>Approximately 50 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response (BOR)</measure>
    <time_frame>Approximately 50 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Approximately 50 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 week BMS-986205 monotherapy lead in followed by BMS-986205 + Nivo combination therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986205</intervention_name>
    <description>Specified Dose on Specified Day</description>
    <arm_group_label>Experimental Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Specified Dose on Specified Day</description>
    <arm_group_label>Experimental Arm A</arm_group_label>
    <other_name>BMS-936558</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants must have histologic or cytological confirmation of a solid tumor that is
             advanced with measureable disease per RECIST v1.1

          -  Participants must have received, and then progressed or been intolerant to at least
             one standard treatment regimen in the advanced or metastatic setting

          -  Participants must have an ECOG performance status of less than or equal to 1

          -  Participants must have at least 1 lesion with measurable disease as defined by RECIST
             Version 1.1

        Exclusion Criteria:

          -  Participants must not have suspected, known, or progressive CNS metastases, have
             untreated CNS metastases, or have the CNS as the only site of disease

          -  Participants with prior exposure to anti PD-1 or anti-PDL1 therapy

          -  Participants must not have a history of allergy to any of the study treatment
             components
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.bms.com/researchers-and-partners/investigator-inquiry-form.html</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 2, 2019</study_first_submitted>
  <study_first_submitted_qc>January 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 3, 2019</study_first_posted>
  <last_update_submitted>January 24, 2020</last_update_submitted>
  <last_update_submitted_qc>January 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual patient level data from this study may be shared with qualified researchers, upon request, following the timelines and process detailed on https://www.bms.com/researchers-and-partners/independent-research/data-sharing-request-process.html</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

